Souhaitez-vous accéder aux communiqués récents ?

KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated...

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...

Persephone Biosciences Announces Publication in Cell Host & Microbe Highlighting the Critical Need to Restore Bifidobacterium in the Infant Gut Microbiome

Washington, DC, Oct. 29, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) today calls on Congress to take immediate action to make health insurance more affordable by...

Washington D.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- A new study published in JAMA finds that the propellants in metered-dose inhalers (MDIs) for the treatment of asthma and COPD contribute...

Washington, DC, Sept. 16, 2025 (GLOBE NEWSWIRE) -- A perfect storm of factors comes together to make September the most challenging month of the year for controlling asthma. Kids going back to...

Washington, DC, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) today released its annual Asthma Capitals™ Report, ranking the top 100 most challenging places...

Persephone Biosciences Unveils First-Of-Its-Kind Synbiotic Designed To Restore Critical Gut Microbes In Babies

Persephone Biosciences Hits 10,000 Families on Waitlist for First-of-Its-Kind Infant Synbiotic